Baralgetas solution intravenously and intramuscularly 5ml No. 5

Instructions

The instructions contain important information that should be read carefully. This must be done in order to avoid errors in the future.

pharmachologic effect

The effectiveness of Bralgetas in the treatment of pathologies accompanied by pain is due to the combination of certain components in its composition. Each of the active ingredients has its own pharmacological properties, which are enhanced by auxiliary elements. The drug acts on the area of ​​inflammation, relaxes the smooth muscle layer and inhibits the synthesis of prostaglandins. Pain relief occurs within thirty minutes.

The drug is dispensed from pharmacies only after presenting a prescription from your doctor. Pharmacological properties:

• m-anticholinergic effect;
• antipyretic effect;
• reduction of symptoms of the inflammatory process;
• papaverine-like effect on smooth muscles;
• relief of pain syndromes of various origins.

Indications

The use of Baralgetas is justified in case of weakness. as well as moderate pain caused by muscle spasms, for example, ureters, biliary and intestinal colic. This remedy can be taken for dyskinesia of the bile ducts, algodismenorrhea, chronic colitis, pelvic diseases, as well as postcholecystectomy syndrome.

The drug can also be used for short-term treatment of arthralgia, myalgia and ischalgia. In addition, very often the product is used after surgery to relieve pain.

Mode of application

Only the attending physician can select the required dosage, as well as the duration of treatment. Pills. Adults should take no more than 2 tablets 2 times a day.

For children, the dosage is selected based on the child’s age and weight:

• 5-7 years old - the dosage is no more than 1/2 tablet, the maximum dosage per day can be no more than 2 tablets;
• 8-11 years old - the dosage can be 1/2 tablet, a child can be given no more than 4 tablets per day;
• 12-14 years - the dose should be no more than 1 tablet at a time. You can give no more than 6 tablets per day.

Solution. The drug in injection form can be administered to adolescents from 15 years of age, as well as to adults in a dosage of 2 ml. The drug must be administered intravenously very slowly, i.e. 1 ml in 1 min. If required, the solution is reintroduced after 6 hours. When administered intramuscularly, the drug Baralgetas is administered 2-3 times, 2-5 ml each. The maximum allowed dosage per day is 10 ml.

Treatment can last 5 days.

To select a dosage for children, it is important to take into account the age of the baby:

• 
  Solution for intramuscular and intravenous administration (Baralgetas). 3-11 months - the drug Baralgetas can only be administered intramuscularly. The dosage should be no more than 0.2 ml;

• 1-2 years old. At this age, intramuscular administration in a dose of 0.3 ml as well as intravenous (0.2 ml) is allowed;
• 3-4 years old. The medicine is administered intravenously in a dosage of 0.3 ml, as well as intramuscularly (0.4 ml);
• 5-7 years. The drug is administered intravenously (04 ml) or intramuscularly (0.5 ml);
• At 8-12 years of age, it is allowed to take the medicine intravenously in a dose of 0.6 ml or intramuscularly. The dosage is 0.7 ml.

Before administering the injection, the ampoule needs to be slightly warmed in your hand.

Release form

In pharmacies you can find 2 forms of medication release:

• Pills;
• Solution.

The tablets/solution contain metamizole sodium, fenpiverinium bromide, and pitofenone hydrochloride.

Interaction

The injection solution should never be combined with other drugs. Concomitant use with alcohol increases the effects of ethanol. Concomitant use with chlorpromazine can provoke the development of hyperthermia.

Contraceptives, antidepressants and allopurine increase the toxicity of Baralgetas. When Baralgetas and cyclosporine are taken simultaneously, the concentration of the latter in the human blood decreases several times.

The effectiveness of the drug is increased several times: codeine, propranolol.

Indications for use Baralgetas

1. The drug is taken to eliminate pain of mild to moderate intensity of various origins.
2. Baralgetas is recommended for spasms of smooth muscles of internal organs that occur with hepatic, intestinal and biliary colic, biliary dyskinesia, and chronic colitis.
3. The effectiveness of this drug for algodismenorrhea and other diseases of the pelvic organs has been proven.
4. Baralgetas is often used for short-term symptomatic treatment of diseases such as ischalgia, neuralgia, arthralgia and myalgia.
5. This drug can act as an adjuvant in eliminating the consequences of certain diagnostic and surgical procedures.
6. Practice confirms that Baralgetas helps normalize body temperature, relieve headaches and relieve aching joints during infectious, inflammatory and colds.

Side effects

• Angioedema, shock, necrolysis, erythema, bronchospasm;
• Anuria, change in urine color (this does not affect the tests in any way), nephritis, proteinuria, and oliguria;
• Thrombocytopenia, agranulocytosis and leukopenia;
• A sharp decrease in blood pressure;
• Tachycardia, dry mouth, decreased/increased sweating, accommodation paresis.

In case of overdose, symptoms such as drowsiness, abdominal pain, vomiting, convulsions, a sharp decrease in blood pressure, and disturbances in kidney function are observed. If this condition occurs, the patient’s stomach is washed using any available method, and activated charcoal is also given.

Contraindications

This drug should not be taken for conditions such as:

• Allergy to components included in the product;
• Severe form of renal/liver failure;
• Angina pectoris, glaucoma, intestinal obstruction, hyperplasia, tachyarrhythmia;
• Collapse and also megacolon.

In addition, the contraindication for intravenous administration of the solution is the child’s age (up to 3 months), and for tablets - 5 years.

In addition, the drug should be prescribed carefully if there is an as triad.

Pregnancy

During pregnancy it is better not to use this remedy. This is due to the fact that the medicine can have a negative effect on the fetus.

During breastfeeding, you should also avoid taking the drug. This is due to the fact that the medicine can have a negative effect on the baby. If you can’t stop taking it, then you need to decide on stopping natural feeding.

To prevent the manifestation of this unpleasant illness, you should, without delay, treat all disorders of a neurotic nature and avoid serious stressful situations.

Interaction with other medications

When using this medication together with other substances and medications, you may be at risk of a number of side effects.

The following information will help you avoid mistakes:

• It is unacceptable to combine alcohol and Baralgetas;
• The use of this medicine together with other non-narcotic analgesics is excluded, since in this case the side effect will be a mutual increase in their toxicity;
• Baralgetas is harmful when taken simultaneously with tricyclic antidepressants and contraceptives, since the latter interfere with the metabolism of metamizole in the liver;
• Tranquilizers and sedatives can enhance the analgesic effect of Baralgetas.

Baralgetas is a very serious combined drug that acts as an analgesic, anti-inflammatory and antispasmodic agent. If you do not know whether the use of the medicine is acceptable in your case, or whether you have any contraindications to Baralgetas, it is better to consult your doctor before starting treatment. And remember that long-term uncontrolled use of painkillers never occurs without negative consequences for health.

special instructions

Impact on the ability to drive vehicles and operate machinery

Baralgetas may reduce the speed of psychomotor reactions. During therapy, it is recommended to exclude potentially hazardous activities that require maintaining concentration. You must also stop driving a car.

Pregnancy and lactation

The injection solution is not used to relieve acute abdominal pain until the cause is determined. The manufacturer lists pregnancy as a contraindication for the use of Baralgetas. It is strictly forbidden to take the drug in the first six weeks of gestation. The medication is not compatible with the lactation period. Breastfeeding should be stopped during therapy.

Use in childhood

Baralgetas is used in pediatrics, but has age restrictions. In the form of a solution, the drug is prohibited for children under three months and weighing less than five kilograms. The tablets can only be taken from the age of five.

For kidney problems

The instructions warn against self-administration of Baralgetas in case of kidney dysfunction. In the presence of such pathologies, the drug is used with caution. Severe renal failure is considered an absolute contraindication for the use of an analgesic.

For liver disorders

Severe liver failure is a contraindication for the use of Baralgetas. For other liver dysfunctions, the drug is recommended to be used with caution.

Conditions for dispensing from pharmacies

Baralgetas is sold in pharmacies by prescription.

Baralgetas No. 100 tablets

Baralgetas-Jugoremedija

Pharmacological action: The drug contains: the non-narcotic analgesic metamizole sodium (analgin), the myotropic antispasmodic drug pitofenon and the m-anticholinergic drug fenpiverinium bromide. Metamizole is a pyrazolone derivative. It has analgesic, antipyretic and anti-inflammatory effects. Pitophenone, like papaverine, has a direct myotropic effect on the smooth muscles of internal organs and causes its relaxation. Phenpiverinium, due to its m-anticholinergic effect, has an additional relaxing effect on smooth muscles. The combination of the three components of the drug leads to pain relief, relaxation of smooth muscles, and a decrease in elevated body temperature. Pharmacokinetics: When taken orally, metamizole sodium, which is part of the drug, is quickly and completely absorbed. T1/2 is reached after 1.4 hours. Metabolized in the liver to form 4-N-methylaminophenazone, 4-aminophenazone, 4-N-acetylaminophenazone and 4-N-formylaminophenazone. T1/2 of the main metabolite 4-N-methylaminophenazone is 1.8-4.6 hours. Penetrates through the placenta and into breast milk. Excreted from the body through the kidneys. Indications for use: Mild or moderate pain syndrome due to spasms of smooth muscles of internal organs - renal and hepatic colic, spastic pain along the intestines, algodismenorrhea. Can be used for short-term symptomatic treatment of joint pain, neuralgia, sciatica, myalgia. As an adjuvant it can be used to reduce pain after surgical and diagnostic interventions. If necessary, the drug can be used to reduce elevated body temperature during colds and infectious and inflammatory diseases. Directions for use: Adults and children over 15 years of age take orally (preferably after meals), usually 1 - 2 tablets 2 - 3 times a day. The daily dose should not exceed 6 tablets. Duration of administration is no more than 5 days. Increasing the daily dose of the drug or the duration of treatment is possible only on the recommendation and under the supervision of a physician. Dosages for children. In children, the drug is used only as prescribed by a doctor. Dosage for children 6-8 years old - half a tablet, 9-12 years old - three quarters of a tablet, 13-15 years old - one tablet 2-3 times a day. Other dosage regimens are possible only after consultation with a doctor. Parenterally (i.v., i.m.). For adults and adolescents over 15 years of age with acute severe colic, 2 ml are administered intravenously slowly (1 ml over 1 minute); if necessary, re-inject after 6-8 hours. IM - 2-5 ml of solution 2-3 times a day. The daily dose should not exceed 10 ml. The duration of treatment is no more than 5 days. Dose calculation for children with IV and IM administration: 3-11 months (5-8 kg) - IM only - 0.1-0.2 ml; 1-2 years (9-15 kg) - IV - 0.1-0.2 ml, IM - 0.2-0.3 ml; 3-4 years (16-23 kg) - IV - 0.2-0.3, IM - 0.3-0.4 ml; 5-7 years (24-30 kg) - IV - 0.3-0.4 ml, IM - 0.4-0.5 ml; 8-12 years (31-45 kg) - IV - 0.5-0.6 ml, IM - 0.6-0.7 ml; 12-15 years - IV and IM - 0.8-1 ml. Before administering the injection solution, it should be warmed in your hand. Side effects: Allergic reactions: urticaria (including on the conjunctiva and mucous membranes of the nasopharynx), angioedema, in rare cases - malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), bronchospastic syndrome, anaphylactic shock. From the urinary system: impaired renal function, oliguria, anuria, proteinuria, interstitial nephritis, red staining of urine. From the cardiovascular system: decreased blood pressure. From the hematopoietic organs: thrombocytopenia, leukopenia, agranulocytosis (may be manifested by the following symptoms: unmotivated rise in temperature, chills, sore throat, difficulty swallowing, stomatitis, as well as the development of vaginitis or proctitis). Anticholinergic effects: dry mouth, decreased sweating, accommodation paresis, tachycardia, difficulty urinating. Local reactions: with intramuscular injection, infiltrates at the injection site are possible. Overdose. Symptoms: vomiting, decreased blood pressure, drowsiness, confusion, nausea, pain in the epigastric region, impaired liver and kidney function, convulsions. Treatment: gastric lavage, administration of activated carbon, symptomatic therapy. Contraindications: Hypersensitivity (including to pyrazolone derivatives), inhibition of bone marrow hematopoiesis, severe hepatic and/or renal failure, glucose-6-phosphate dehydrogenase deficiency, tachyarrhythmias, severe angina pectoris, decompensated CHF, angle-closure glaucoma, prostatic hyperplasia (with clinical manifestations) , intestinal obstruction, megacolon, collapse, pregnancy (especially in the first trimester and the last 6 weeks), lactation. For intravenous administration - infancy (up to 3 months) or body weight less than 5 kg. For tablets - children's age (up to 5 years). With caution. Renal/liver failure, bronchial acid triad, tendency to arterial hypotension, hypersensitivity to other non-steroidal anti-inflammatory drugs.

Drug interactions: Solution for injection is pharmaceutically incompatible with other drugs. When administered together with H1-histamine blockers, butyrophenones, phenothiazines, tricyclic antidepressants, amantadine and quinidine, the m-anticholinergic effect may be enhanced. Enhances the effects of ethanol; simultaneous use with chlorpromazine or other phenothiazine derivatives can lead to the development of severe hyperthermia. Tricyclic antidepressants, oral contraceptives and allopurinol increase the toxicity of the drug. Phenylbutazone, barbiturates and other hepatoinducers, when administered simultaneously, reduce the effectiveness of metamizole sodium. Sedative and anxiolytic drugs (tranquilizers) enhance the analgesic effect of metamizole sodium. Radiocontrast drugs, colloidal blood substitutes and penicillin should not be used during treatment with drugs containing metamizole sodium. With simultaneous administration of cyclosporine, the concentration of the latter in the blood decreases. Metamizole sodium, displacing oral hypoglycemic drugs, indirect anticoagulants, corticosteroids and indomethacin from protein binding, can increase the severity of their action. Thiamazole and cytostatics increase the risk of developing leukopenia. The effect is enhanced by codeine, H2-histamine receptor blockers and propranolol (slows down the inactivation of metamizole sodium). Release form: Tablets - 10 tablets in blister packs. The cardboard box contains 10 blisters and instructions for medical use. Solution for intravenous and intramuscular administration (dark glass ampoules) 5 ml. Storage conditions: List B. At a temperature not exceeding +25 C in a dry place, protected from light, out of reach of children. Conditions of release: by doctor's prescription. Composition: Flat-cylindrical tablets from white to light yellow, with chamfers and a score on one side. Marbling is allowed. Each tablet contains: active ingredients: metamizole sodium - 500 mg, pitofenone hydrochloride - 5.0 mg, fenpiverinium bromide - 0.1 mg; excipients: lactose, starch, sodium bicarbonate, talc, magnesium stearate. Each ampoule contains: metamizole sodium 500 mg, pitofenone 2 mg, fenpiverinium bromide 20 mcg, excipients (water for injection, hydrochloric acid 1mol/l) - 1 ml. Additionally: During treatment with the drug, it is not recommended to take ethanol. With long-term (more than a week) treatment, monitoring of the peripheral blood picture and the functional state of the liver is necessary. If agranulocytosis is suspected or thrombocytopenia is present, the drug should be discontinued. It is not permissible to use it to relieve acute abdominal pain (until the cause is determined). Use in nursing mothers requires cessation of breastfeeding. Intolerance is very rare, but the risk of developing anaphylactic shock after intravenous administration of the drug is relatively higher than after taking the drug orally. Patients with atopic bronchial asthma and hay fever have an increased risk of developing allergic reactions. Parenteral administration should be used only in cases where oral administration is not possible (or absorption from the gastrointestinal tract is impaired). Special caution is required when administering more than 2 ml of solution (risk of a sharp decrease in blood pressure). The IV injection should be carried out slowly, in the “lying” position and under the control of blood pressure, heart rate and respiratory rate. When treating children under 5 years of age and patients receiving cytostatic drugs, metamizole sodium should only be taken under medical supervision. For intramuscular administration it is necessary to use a long needle. It is possible that the urine may turn red due to the release of a metabolite (it has no clinical significance). During treatment, drivers of vehicles and persons engaged in potentially hazardous activities that require quick physical and mental reactions should be careful.

Storage method

The drug should be stored at room temperature in a place where children will not have access. The place should also be protected from moisture and light.

If all conditions are met, both dosage forms of the drug can be stored for 5 years. After the expiration date has expired, it is prohibited to continue using the drug.

Did you know that the most common diseases of the 21st century are liver problems? More details:

• How to recognize the first signs of hepatitis and effectively cope with the disease?
• An interesting article about liver cirrhosis, you will learn about the history of the disease and its prevalence in the world.
• Pain or discomfort in the right hypochondrium? Perhaps it's hepatosis! How can it be cured?

Analogs

This drug has a large number of similar products. Among the direct analogues are: Plenalgin, Geomag, Spazmalin, Spazgan, Bral, Maxigan, Spazmoblok, Trinalgin, Spazmograd, Renalgan, Revalgin, Bralangin, Spazmalgon.

Among the drugs that have the same effect on the body are: Andipal, Akofil, Quatrox, Benalgin, Tempalgin, Sedal-M, Tetralgin, Pentabufen, Beralgin M, Analgin, Antipirin, Santoperalgin, Quintalgin, Tempanginol.